PDCD1 and neoplasm: EBPs derived from tumor cells overexpressing the high-affinity variant human PD-1 protein (havPD-1) can block the function of highly expressed PD-L1 in tumors, induce tumor cell apoptosis, and activate cytotoxic T cells in combination with low-dose PARP inhibitors, thereby effectively treating homotypic tumors [52].